CFPs: Grants for Research and Development in Vaccine and Pharmaceutical Manufacturing (Ghana)

The PharmaVax Ghana programme is part of the Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines and Health Technologies in Africa (MAV+) and is co-financed by the European Union (EU) and the German Federal Ministry for Economic Cooperation and Development (BMZ).

Objectives

• Identify impactful and innovative vaccine and pharmaceutical R&D projects that are relevant to public health in Ghana and Africa.
• Support concrete R&D projects jointly led and carried out by Ghanaian research institutions and pharmaceutical manufacturers, thereby fostering partnerships and local innovation.
• Contribute to innovation in discovery and product development in Ghana as well as sustainable commercialisation of locally manufactured vaccines and other pharmaceutical products.
• Support Ghanaian stakeholders in strengthening their R&D capacity, sharing results of the R&D projects and build their capacities to apply for further large-scale R&D grants.

Focus Areas

• Improving the capacities of public actors for governance and regulation of pharmaceutical production,
• Supporting skills development for pharmaceutical workforce,
• Promoting applied research and development through cooperation of the pharmaceutical industry and research institutions,
• Private sector development to strengthen manufacturers’ production capacities and market access.

Thematic Areas

• Vaccines (including biosimilars) and other biological products
• Sera including anti-venoms
• Herbal medicines
• Medicines for Neglected Tropical Diseases (NTDs) and orphan drugs
• Medicines for conditions of public health relevance in Ghana including Non Communicable Diseases (NCDs) and infectious diseases
• Medical diagnostics for preliminary or emergency medical screening and devices for drug application
• Veterinary vaccines (other veterinary drugs are not eligible

Funding Information

• Three funding windows are available for projects spanning a maximum period of 24 months: up to EUR 125,000; up to EUR 300,000; up to EUR 500,000.
• Project duration and end Up to 24 months (up to November 2027)

Eligible Costs

• Staff costs
• External services
• Transport costs/travel expenses
• CO2 compensation for flights
• Procurement of materials and equipment
• Other costs/consumables
• Funds for direct support to third party beneficiaries
• Fair-shared costs
• Administrative costs (pro rata on the reported direct costs, please indicate %)
• Forwarding of funds to third party recipients

Ineligible Costs

• Staff bonuses, provisions, reserves or non-remuneration-related costs
• Debts and debt service charges
• Provision for losses, debts or potential future liabilities
• Costs of purchase of land or buildings
• Purchase of vehicles 6. Construction costs

Eligible Projects

• The screening, identification, as well as efficacy and safety testing for (innovative) chemical and biological molecules in the context of (clinical) development of drugs including herbals, vaccines and sera.
• Innovations in product formulation (e.g. formulations, prolonged release formulations, biosimilars, generics) medical diagnostics and devices for drug application, and product development for under-served patient groups.
• (FDA-approved) Clinical trials of drugs including herbals, vaccines and sera and medical diagnostics and devices for drug application.

Eligibility Criteria

• The technical scope of the proposed R&D project must fall within the requirements.
• The public benefit of the proposed project must be clearly stated and explained in the proposal.
• The lead applicant must be a Ghanaian research institution, i.e. a locally registered public or private entity that has research as a primary organisational objective (e.g. public or private academic departments or research institutes, private R&D companies).
• The proposal must involve at least one FDA-approved, private or public Ghanaian pharmaceutical manufacturer as a co-applicant. The involvement must be proven through a letter of engagement by the manufacturer. This is to be attached to the proposal. The proposal should clearly describe the intended involvement, the contributions (financial, in-kind) and the interest of the manufacturer.

For more information, visit GIZ.